Chengdu Young-Med Biotechnology

Chengdu Young-Med Biotechnology is a clinical-stage biopharmaceutical company specializing in the development of next-generation peptide therapeutics for metabolic diseases. Founded in 2021 and headquartered in Chengdu, China, the company leverages a proprietary peptide modification platform to create long-acting treatments for obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). Its lead candidate, YM-001, is a triple agonist targeting the GLP-1, GIP, and glucagon receptors, currently undergoing Phase 1 clinical trials. The company's technology focuses on optimizing peptide sequences and utilizing fatty acid side-chain engineering to enhance drug stability and half-life. Young-Med is supported by prominent venture capital firms, including IDG Capital and GL Ventures, positioning it as a key innovator in the rapidly evolving metabolic health sector.